217 related articles for article (PubMed ID: 7528949)
1. Fibrinolytic activity during orthotopic liver transplantation with and without aprotinin.
Segal HC; Hunt BJ; Cottam S; Downing A; Beard C; Francis JL; Potter D; Tan KC
Transplantation; 1994 Dec; 58(12):1356-60. PubMed ID: 7528949
[TBL] [Abstract][Full Text] [Related]
2. Evolution of urokinase-type plasminogen activator (u-PA) and tissue-type plasminogen activator (t-PA) in orthotopic liver transplantation (OLT).
Himmelreich G; Dooijewaard G; Breinl P; Bechstein WO; Neuhaus P; Kluft C; Riess H
Thromb Haemost; 1993 Jan; 69(1):56-9. PubMed ID: 8446939
[TBL] [Abstract][Full Text] [Related]
3. Changes in the contact system during orthotopic liver transplantation with and without aprotinin.
Segal HC; Hunt BJ; Cottam S; Beard C; Francis JL; Potter D; Tan KC
Transplantation; 1995 Feb; 59(3):366-70. PubMed ID: 7532878
[TBL] [Abstract][Full Text] [Related]
4. Plasma MMP-2 and MMP-9 and their inhibitors TIMP-1 and TIMP-2 during human orthotopic liver transplantation. The effect of aprotinin and the relation to ischemia/reperfusion injury.
Kuyvenhoven JP; Molenaar IQ; Verspaget HW; Veldman MG; Palareti G; Legnani C; Moolenburgh SE; Terpstra OT; Lamers CB; van Hoek B; Porte RJ
Thromb Haemost; 2004 Mar; 91(3):506-13. PubMed ID: 14983226
[TBL] [Abstract][Full Text] [Related]
5. Hemostasis and blood requirements in orthotopic liver transplantation with and without high-dose aprotinin.
Llamas P; Cabrera R; Gómez-Arnau J; Fernández MN
Haematologica; 1998 Apr; 83(4):338-46. PubMed ID: 9592984
[TBL] [Abstract][Full Text] [Related]
6. Aprotinin in orthotopic liver transplantation: evidence for a prohemostatic, but not a prothrombotic, effect.
Molenaar IQ; Legnani C; Groenland TH; Palareti G; Begliomini B; Terpstra OT; Porte RJ
Liver Transpl; 2001 Oct; 7(10):896-903. PubMed ID: 11679989
[TBL] [Abstract][Full Text] [Related]
7. Changes in urokinase-type plasminogen activator in orthotopic liver transplantation.
Himmelreich G; Dooijewaard G; Breinl P; Bechstein WO; Blumhardt G; Kluft C; Riess H
Semin Thromb Hemost; 1993; 19(3):311-4. PubMed ID: 7689759
[TBL] [Abstract][Full Text] [Related]
8. Increased urokinase-type plasminogen activator (u-PA) levels in graft liver perfusate and decreased single chain u-PA activation with higher levels of aprotinin.
Himmelreich G; Dooijewaard G; Neuhaus P; Kluft C; Bechstein WO; Riess H
Thromb Haemost; 1994 Jan; 71(1):12-4. PubMed ID: 7513093
[TBL] [Abstract][Full Text] [Related]
9. Coagulation and fibrinolysis in primary biliary cirrhosis compared with other liver disease and during orthotopic liver transplantation.
Segal H; Cottam S; Potter D; Hunt BJ
Hepatology; 1997 Mar; 25(3):683-8. PubMed ID: 9049219
[TBL] [Abstract][Full Text] [Related]
10. Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass.
Spannagl M; Dooijewaard G; Dietrich W; Kluft C
Thromb Haemost; 1995 May; 73(5):825-8. PubMed ID: 7482410
[TBL] [Abstract][Full Text] [Related]
11. Diurnal variation of the fibrinolytic system.
Grimaudo V; Hauert J; Bachmann F; Kruithof EK
Thromb Haemost; 1988 Jun; 59(3):495-9. PubMed ID: 3142085
[TBL] [Abstract][Full Text] [Related]
12. PAI-1 plays an important role in the expression of t-PA activity in the euglobulin clot lysis by controlling the concentration of free t-PA.
Urano T; Sumiyoshi K; Pietraszek MH; Takada Y; Takada A
Thromb Haemost; 1991 Oct; 66(4):474-8. PubMed ID: 1796399
[TBL] [Abstract][Full Text] [Related]
13. Fibrinolysis system in patients with bronchial asthma.
Banach-Wawrzeńczyk E; Dziedziczko A; Rość D
Med Sci Monit; 2000; 6(1):103-7. PubMed ID: 11208294
[TBL] [Abstract][Full Text] [Related]
14. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
[TBL] [Abstract][Full Text] [Related]
15. Retinoic acid enhances fibrinolytic activity in-vivo by enhancing tissue type plasminogen activator (t-PA) activity and inhibits venous thrombosis.
van Giezen JJ; Boon GI; Jansen JW; Bouma BN
Thromb Haemost; 1993 Apr; 69(4):381-6. PubMed ID: 8497851
[TBL] [Abstract][Full Text] [Related]
16. Postoperative hemostasis and fibrinolysis in patients undergoing cardiopulmonary bypass with or without aprotinin therapy.
Lu H; Du Buit C; Soria J; Touchot B; Chollet B; Commin PL; Conseiller C; Echter E; Soria C
Thromb Haemost; 1994 Sep; 72(3):438-43. PubMed ID: 7531877
[TBL] [Abstract][Full Text] [Related]
17. Hyperfibrinolysis in alcoholic cirrhosis: relative plasminogen activator inhibitor type 1 deficiency.
Ferguson JW; Helmy A; Ludlam C; Webb DJ; Hayes PC; Newby DC
Thromb Res; 2008; 121(5):675-80. PubMed ID: 17870147
[TBL] [Abstract][Full Text] [Related]
18. Fibrinolysis in patients with acute ischaemic heart disease. With particular reference to systemic effects of tissue-type plasminogen activator treatment on fibrinolysis, coagulation and complement pathways.
Munkvad S
Dan Med Bull; 1993 Sep; 40(4):383-408. PubMed ID: 8222763
[TBL] [Abstract][Full Text] [Related]
19. Fibrinolytic activity in peripheral atherosclerosis in the elderly.
van der Bom JG; Bots ML; Haverkate F; Meyer P; Hofman A; Grobbee DE; Kluft C
Thromb Haemost; 1999 Feb; 81(2):275-80. PubMed ID: 10064006
[TBL] [Abstract][Full Text] [Related]
20. Mediators of fibrinolysis in orthotopic liver transplantation.
Cheema SP; Webster NR; Dunn F; Bellamy MC
Clin Transplant; 1996 Feb; 10(1 Pt 1):24-7. PubMed ID: 8652893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
